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Abstract Osteoarthritis (OA) is a chronic degenerative
joint disease characterized by the progressive loss of ar-
ticular cartilage, remodeling of the subchondral bone, and
synovial inflammation. Mammalian target of rapamycin
(mTOR) is a serine/threonine protein kinase that controls
critical cellular processes such as growth, proliferation, and
protein synthesis. Recent studies suggest that mTOR plays
a vital role in cartilage growth and development and in
altering the articular cartilage homeostasis as well as
contributing to the process of cartilage degeneration asso-
ciated with OA. Both pharmacological inhibition and ge-
netic deletion of mTOR have been shown to reduce the
severity of OA in preclinical mouse models. In this review
article, we discuss the roles of mTOR in cartilage devel-
opment, in maintaining articular cartilage homeostasis, and
its potential as an OA therapeutic target.
1 Introduction
Aging is known to be one of the major risk factors pre-
cipitating the onset of osteoarthritis (OA) [1–3]. Although
aging and OA are correlative, OA is not a predictable
consequence of aging, since other factors such as obesity,
joint injury, and genetics may come into play [1]. Among
the early signs of OA is alteration in the extracellular
matrix (ECM) composition within the articular cartilage.
This elicits a chondrocytic, synthetic, and proliferative
response that functions to maintain or restore the articular
cartilage. With advancing age, there is a decline in the
chondrocytic anabolic response, ultimately favouring ma-
trix degradation [2–4]. The joint tissue is therefore unable
to bear normal load or maintain homeostasis when stressed,
which leads to matrix destruction and disease progression.
Destruction of the ECM of articular cartilage is a major
indicator of OA [5]. With advanced age, chondrocytes
exhibit reduced responsiveness to growth factors, abnormal
accumulation of advanced glycation end products (AGE),
mitochondrial dysfunction, and oxidative stress. As a re-
sult, cartilage homeostasis is disrupted and the ECM be-
comes more vulnerable to damage, leading to the onset of
OA [6]. Chondrocytes are the one cell type present in the
articular cartilage and are exclusively responsible for ma-
trix turnover and maintenance [7]. They function to
maintain cartilage homeostasis by maintaining a condition
where the normal cartilage ECM composition deals with
mechanical stress without structural or cellular damage [5].
With OA progression, excessive catabolic activity is
largely mediated by proinflammatory cytokines and me-
diators such as matrix metalloproteinases (MMPs) and a
disintegrin and metalloproteinase with thrombospondin
motifs (ADAMTS) [6]. The breakdown of cartilage during
OA pathogenesis is also a result of chondrocyte death as
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evidenced by the presence of apoptotic and non-apoptotic
mechanisms in OA cartilage [8]. This excessive catabolic
activity and loss of viable chondrocytes causes imbalance
of cartilage homeostasis and cartilage matrix breakdown.
There is also minimal proliferative activity in osteoarthritic
chondrocytes, in contrast to essentially no proliferative
activity in normal articular chondrocytes. In response to
injury during OA progression, chondrocytes proliferate and
form clusters, a characteristic feature of OA cartilage, in an
attempt to repair cartilage lesions. In spite of attempts to
salvage the cartilage degeneration, cartilage homeostasis
cannot be maintained, as the biosynthetic anabolic activity
becomes unable to compete with the degradative catabolic
activity [9, 10].
Studies suggest that cellular processes such as au-
tophagy and senescence could play a key role in deter-
mining the fate of chondrocytes within the articular
cartilage. Mammalian cells maintain homeostatic func-
tions such as the degradation and recycling of organelles
via autophagy [11]. Autophagy is the process of cell
degradation in a stressful or nutrient-deprived environ-
ment, consisting of formation of an isolation membrane,
or autophagosome, around the contents to be degraded,
which combines with a lysosome to form an autolyso-
some. This lysosomal degradation pathway is essential for
homeostasis as well as survival, differentiation, and de-
velopment [12]. Autophagy is particularly important to
remove aggregate-prone or misfolded proteins and dys-
functional organelles in post-mitotic tissue, such as the
articular cartilage, where a very low rate of cell turnover
is experienced [13]. The molecular components that
control the autophagy process, the Atg genes, were first
identified in yeast. Among the Atg genes, the four major
regulators of the autophagy pathway are Atg1, Atg6, Atg8
(ULK1, Beclin1, and LC3 in mammals, respectively) and
Atg5 [14]. ULK1 is a serine/threonine kinase that func-
tions as an intermediate in the transduction of proau-
tophagic signals to autophagosome formation [15].
Beclin1 forms a complex with type II phosphatidylinositol
3-kinase (PI3K) and Vps34 allowing nucleation of the
autophagic vesicle [16]. LC3 is present in two forms:
LC3-I is located in the cytoplasm, while LC3-II is bound
to the autophagosome membrane. During autophagy,
LC3-I undergoes lipidation to be converted to LC3-II,
resulting in the association of LC3-II with autophagy
vesicles [17].
The reduced efficacy of articular cartilage repair that
accompanies ECM degradation has also been proposed to
be a result of chondrocyte phenotypic senescence [18]. As
opposed to ‘replicative senescence’, which refers to the
loss of the ability of mitotic cells to further divide in
culture after a period of 30–40 population doublings
(‘Hayflick limit’), phenotypic senescence develops well in
advance of complete arrest of the cell cycle [1, 19]. De-
terioration of chondrocyte function with age is character-
ized by a decline in their mitotic and synthetic activity,
resulting in the synthesis of smaller proteoglycan aggre-
gates. This is due to the shortening of aggrecan molecules,
their chondroitin sulfate chains, and the reduction in the
mean number of aggrecans in each aggregate. These age-
related incidents may be a result of ECM proteoglycan
degradation and/or alterations in proteoglycan synthesis
[20]. Using three markers of cell senescence (beta-galac-
tosidase expression, mitotic activity, and telomere length),
studies conducted by Martin and Buckwalter [18] showed
that beta-galactosidase expression increased with age,
whereas mitotic activity (indicated by 3H-thymidine in-
corporation) and mean telomere length declined with age.
Two mechanisms have been proposed to explain how the
cells become senescent with age [18]. First, telomere
erosion occurs as a result of incomplete replication of the
telomeres during mitosis (end replication problem) such
that a portion of the end of the telomere is lost with each
cell division. As telomeres shorten, cells ultimately reach
their replicative limit and progress into senescence [21].
While authors such as Loeser [1] argue that telomere
erosion due to repeated cycles of cell division does not
explain senescence in quiescent cells such as chondro-
cytes, Martin and Buckwalter [18] claim that even a slow
rate of cell division would be sufficient to cause telomere
erosion over many decades. Additionally, following car-
tilage injury, chondrocyte mitotic activity increases sev-
eral fold; hence, repetitive joint stress could accelerate
telomere erosion and eventual joint degeneration [22].
Stress-induced senescence due to oxidative damage is the
second proposed mechanism of how cells approach se-
nescence [23]. One causative factor for oxidative damage
is the age-related degeneration of mitochondria, which
protect cells from the toxic effects of free radicals and
reactive oxygen species (ROS) as well as providing
metabolic energy to support the homeostatic activities that
chondrocytes require for tissue maintenance [18, 24].
Mitochondrial degeneration and loss is suggested to be
associated with chondrocyte senescence. The altered ac-
tivity and expression of regulatory proteins that control
cell growth and proliferation in senescent cells can also
result in the increased production of cytokines (e.g. in-
terleukin [IL]-6 and IL-1), growth factors (e.g. epidermal
growth factor), and MMPs. This ‘senescent secretory
phenotype’ can also contribute to tissue aging through
damage to the ECM [1]. While senescent cells undergo
permanent cell cycle arrest, growth-promoting pathways
are not inhibited [25]. The enlarged and flattened cell
morphology is a distinct marker of cell senescence, a
consequence of cell growth without cell divisions (i.e.
cellular hypertrophy) [25, 26].
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2 Mammalian Target of Rapamycin (mTOR)
The target of rapamycin (TOR) is a nutrient-sensing
signaling cascade that is responsible for the regulation of
growth and metabolism of cells, depending on the nutri-
tional environment. The discovery of the TOR pathway
was preceded by the discovery of the drug rapamycin. It
was discovered on the island of Rapa Nui in the 1970s
from the bacteria Streptomyces hygroscopicus and ini-
tially studied as an anti-fungal agent [27]. TOR is a 282
kDa protein composed of an evolutionarily conserved
atypical serine-threonine kinase, part of the phos-
phatidylinositol kinase-related kinase (PIKK) family, also
similar to the PI3K and 4-kinases (PI4Ks). It was
originally discovered in Saccharomyces cerevisiae, where
the immunosuppressant FK506, structurally similar to
rapamycin, was found to bind to FK506-binding protein
(FKBP12), a peptidyl-prolyl isomerase (PPIase), which is
highly conserved across species and a very abundant
protein in cells [28–31].
The TOR pathway can be inhibited by TOR inhibitors,
which bind to FKBP12. This complex then targets and
binds to TOR and inhibits it. Mutations in TOR prevent
the binding of the FKBP12-rapamycin complex to it,
depicting the role of TOR in the pathway [31]. The
mammalian counterpart in mammals, mTOR (or FRAP,
RAFT1 [32]), now known as the mechanistic target of
rapamycin, is inhibited by the FKBP12–rapamycin com-
plex [33]. mTOR comprises of two complexes that are
similar in structure but not in function [34]: while the
mTOR complex 1 (mTORC1) consists of mTOR, mLST8,
and raptor; the mTOR complex 2 (mTORC2) consists of
mTOR, mLST8, and rictor (not raptor). FKBP12–ra-
pamycin complex binds to the raptor component of
TORC1, not the rictor component of TORC2 in vivo,
concluding that TORC1 is rapamycin sensitive while
TORC2 is insensitive [35, 36]. mTORC1 is important for
the regulation and promotion of cell growth, protein
synthesis upstream (initiation, translation, elongation), ri-
bosome biogenesis, cell cycle regulation via the S/G1
phase, inhibition of autophagy, accelerated aging and
nutrient uptake and metabolism (Fig. 1). On the other
hand, mTORC2 controls endocytosis, sphingolipid
biosynthesis (ROS association), cell survival, and polar-
ization of the cytoskeleton [37–40].
mTORC1 is a major negative regulator of autophagy
(discussed in detail later) and is a downstream target of the
PI3K and protein kinase B (Akt) pathway [41–43]. The
PI3K/Akt/mTOR signaling cascade is activated by trans-
membrane tyrosine kinase growth factor receptors such as
insulin-like growth factor (IGF)-1 [44]. When activated, it
promotes cell growth, differentiation, survival, and down-
regulates apoptotic signals [45, 46]. AKT stimulates mTOR
activity by phosphorylating the tuberous sclerosis complex
(TSC2) and suppressing its repressive action [47]. TSC2
phosphorylation consequently promotes the activation of
the Ras homolog enriched in brain (Rheb) and the activa-
tion of mTOR [48]. Activation of mTOR leads to the
phosphorylation of p70 ribosomal S6 kinase (S6K) and
eukaryotic initiation factor 4E-binding protein (4EBP),
which are related to translational machinery, ribosomal
biogenesis, and cell growth [49]. On the other hand, inhi-
bition of mTOR by rapamycin induces the initiation of
autophagy and the formation of autophagosomes [50].
mTORC1 inhibition by rapamycin also increases AKT
phosphorylation by blocking the phosphorylation of S6K
and insulin receptor substrate (IRS)-1, which are key fac-
tors of a negative feedback inhibition for PI3K/Akt signal
transduction, consequently inducing survival and anti-
apoptotic pathways [51, 52].
Fig. 1 Some of the critical physiological and pathological roles of mammalian target of rapamycin. mTOR mammalian target of rapamycin, OA
osteoarthritis
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3 mTOR in Cartilage Growth and Development
Several studies suggest that mTOR plays a vital role in
cartilage growth and development. Chen and Long [53]
showed that disruption of mTORC1 signaling through
deletion of either mTOR or raptor retards embryonic
skeletal growth associated with severe delays in chondro-
cyte hypertrophy and bone formation [53]. This study also
showed that growth reduction of cartilage is not due to
changes in chondrocyte proliferation or survival, but is
caused by a reduction in cell size and in the amount of
cartilage matrix. It has also been shown that mechanical
activation of mTOR is necessary for cell proliferation,
chondrogenesis, and cartilage growth during bone devel-
opment [54]. Rokutanda et al. [55] showed that the Akt–
mTOR pathway positively and dominantly regulates
chondrocyte proliferation, maturation and cartilage matrix
production during skeletal development. Studies also show
that mTOR signaling contributes to chondrocyte differen-
tiation [56].
Rapamycin-treated animals have been shown to exhibit
retarded growth and marked alterations in the growth plate
associated with disruption of angiogenesis in the growth
plate [57]. Direct infusion of rapamycin in growth plates by
an osmotic minipump resulted in smaller hypertrophic and
proliferative zones, decrease in the size of the growth plate,
and inhibition of overall long bone growth in rabbits [58].
In young rats, treatment with rapamycin significantly de-
creased endochondral bone growth [59]. Treatment with
rapamycin has also been shown to inhibit chondrogenesis
of mesenchymal cells at the post-precartilage condensation
stage [60]. It may seem like mTORC1 is essential for
normal cartilage and skeletal development; however, re-
cent reports suggest that mTORC2 also plays a key role in
skeletal development. Chen et al. [61] showed that deletion
of rictor resulted in shorter and narrower skeletal elements
in both embryos and postnatal mice. Specifically, this study
showed that deletion of rictor reduced the width but not the
length of the initial cartilage anlage associated with a delay
in chondrocyte hypertrophy, with no change in prolif-
eration, apoptosis, cell size, or matrix production. Further,
rictor-deficient mice exhibit impaired bone formation, re-
sulting in thinner cortical bone postnatally. These studies
strongly suggest that mTOR is a key regulator of chon-
drogenesis and cartilage development.
4 mTOR in Articular Cartilage Homeostasis
In recent years, a variety of studies have demonstrated a
key role of mTOR signalling in chondrocyte metabolism,
articular cartilage homeostasis, and OA pathophysiology
[62]. Tchetina et al. [63] recently reported an upregulation
in mTOR gene expression in the peripheral blood
mononuclear cells (PBMCs) of OA patients and in the
articular cartilage of all end-stage OA patients. They also
showed that an increase in the expression of mTOR in
PBMCs of OA patients related to disease activity, being
associated with synovitis. Interestingly, this study also re-
ported a ‘‘low mTOR expression subset’’ with significantly
lower mTOR gene expression in PBMCs compared with
healthy controls that correlated with pain upon walking,
standing and increased total joint stiffness compared with
the ‘‘High mTOR’’ subset.
It has also been shown that upregulation in the expres-
sion of mTOR in OA cartilage is accompanied with an
increased rate of chondrocyte apoptosis [64]. Increase in
mTOR expression and an increased rate of chondrocyte
loss is not restricted to human OA cartilage, as mouse and
dog cartilage subjected to OA surgical models also exhibit
a significant increase in mTOR expression associated with
enhanced articular chondrocyte loss [64].
Recent studies have shown that dysregulated autophagy
could contribute to the pathophysiology of OA [4, 64–68].
Carames et al. [4] demonstrated that the expression of key
autophagy markers ULK1 (most upstream autophagy in-
ducer), Beclin1 (autophagy regulator), and LC3 (au-
tophagosome formation) were significantly decreased in
human aging, OA cartilage, chondrocytes, and aging-re-
lated and surgically induced OA mouse models. Further-
more, an increase in apoptotic cell death was observed via
the increased expression of the apoptosis marker, poly
ADP ribose polymerase (PARP) p85, in human aging and
OA cartilage and chondrocytes as well as aging-related and
surgically induced OA mouse models [4]. Data from au-
tophagy polymerase chain reaction (PCR) array analysis
also shows aberrant expression of several autophagy genes
in human OA cartilage compared with normal human
cartilage associated with increased expression of mTOR
during OA [64].
Both pharmacological inhibition of mTOR as well as
cartilage-specific deletion of mTOR have been shown to
decrease the severity of experimental OA in mouse models
[64, 69–71]. Inhibition of mTOR signaling by rapamycin
and subsequent increase in autophagy was shown to be
associated with a significant reduction in the severity of
cartilage degeneration and synovitis associated with de-
crease in the expression of ADAMTS-5 and IL-1b in ar-
ticular cartilage [71]. Further, cartilage-specific mTOR
knock-out (KO) mice subjected to destabilisation of the
medial meniscus in the OA model showed significant
protection from surgery-induced OA, associated with in-
creased autophagy and decreased articular chondrocyte cell
death, elucidating a potential role for mTOR inhibition to
restore homeostasis during OA [64]. Sasaki et al. [65] also
showed that inhibition of autophagy caused OA-like gene
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expression changes, while the induction of autophagy by
rapamycin reduced MMP13 and ADAMTS5 expression
induced by IL-1b, a major pro-inflammatory cytokine im-
plicated in OA [72]. Another study showed that glucocor-
ticosteroids used in the short-term increase autophagy in
human chondrocytes, but cause apoptosis in the long term.
When rapamycin was given before treatment, cell viability
and autophagy increased compared with dexamethasone-
only cells [73].
It has also been shown that mTOR can be regulated via
enhanced synthesis of endogenous n-3 polyunsaturated
fatty acids (PUFAs) from n-6 PUFAs, thus promoting au-
tophagy and chondrocyte cell survival and delaying the
incidence of OA [74]. Genetic deletion of Von Hippel–
Lindau (Vhl), a tumor-suppressor gene, in the articular
cartilage results in increased phosphorylation of mTOR
and increased MMP-13 expression associated with earlier
dysregulation of cartilage homeostasis, increased chon-
drocyte apoptosis, compromised autophagy, and acceler-
ated age-related and surgery-induced OA development
[75]. Phosphoinositide-specific phospholipase c1 (PLCc1),
a key regulator of cell metabolism, has been shown to
regulate the ECM synthesis of human chondrocytes
through triggering of the mTOR/P70S6K/S6 pathway [76].
In vitro and in vivo studies using glucosamine have also
been shown to enhance autophagy associated with the in-
hibition of Akt/mTOR pathway, thus shedding light on
possible disease-modifying or homeostatic properties ex-
hibited by glucosamine [77].
mTOR modulation of autophagy in the articular cartilage
seems to be partly regulated through the ULK1/AMPK
pathway. ULK1 is the most upstream autophagy inducer.
mTORC1 has been shown to associate with the ULK1-
Atg13-FIP200 complex, whereby it phosphorylates both
ULK1 and Atg13, which represses ULK1 kinase activity [3,
78, 79]. Therefore, when mTOR is active in conditions such
as the presence of abundant amino acids, autophagy is re-
pressed as a consequence of ULK1 inhibition by mTORC1-
mediated phosphorylation [80]. Indeed, studies performed
in cartilage-specific mTOR KO mice and human patient OA
cells treated with rapamycin showed that the ability of
mTOR to modulate ULK1/AMPK autophagy pathway may
be partly responsible for the imbalance between catabolic
and anabolic processes and decreased chondroprotection
and ultimately cartilage destruction observed during OA.
Since mTOR is a complex mediator, it may affect other
cellular processes independently of the autophagy pathway
in articular cartilage. For example, mTOR plays a role in
growth-promoting pathways and remains active during
senescence [81]. The significance of active growth-pro-
moting pathways in cellular senescence was shown by
Demidenko et al. [82]. p21 induction caused cell-cycle
arrest in HT1080 human fibrosarcoma cells, as well as a
senescent morphology (beta-galactosidase staining, cell
hypertrophy, increased levels of cyclin D1, active mTOR)
in the presence of serum growth factors. However, the
addition of rapamycin decelerated cellular senescence and
partially reduced beta-galactosidase staining. Still, sup-
pression of the permanent loss of proliferative potential by
rapamycin is only achievable if the cell cycle inhibitors are
removed [82]. Hence, while rapamycin does not reverse
cell cycle arrest, it does suppress inappropriate growth
stimulation via mTOR. These findings have yet to be ex-
amined in the context of chondrocyte senescence.
Since mTOR is active in senescent cells, and mTOR is
also a major repressor of autophagy, one would assume
autophagy to be inhibited in senescent cells. Interestingly,
Narita and colleagues [83, 84] observed that autophagy can
be activated in senescent cells. Their research uncovered a
unique cellular compartment, the TOR-autophagy spatial
coupling compartment (TASCC), which forms during Ras-
induced senescence. The authors discovered a large accu-
mulation of mTORC1-studded lysosomes together with
autophagosomes in a well-defined perinuclear location.
According to their proposed model, autophagosome-
derived amino acids reinforce mTOR enrichment and ac-
tivity, leading to the synthesis of senescence-associated
secretory proteins. Blocking the localization of mTORC1
to the TASCC resulted in a strong reduction in the syn-
thesis of two key SASP components, IL-6 and IL-8.
Similarly, blocking autophagy (i.e. cutting off amino acid
supply) leads to a complete loss of mTORC1 from the
TASCC [83, 85]. Thus, there is increasing evidence that the
progressive loss of cell function with age contributes to
age-related changes in articular cartilage structure and
function and increases the risk of the articular cartilage
degeneration associated with OA. Furthermore, mTOR has
been shown to have significant roles in both autophagy and
senescence, as well as its recently discovered role fa-
cilitating the mass synthesis of secretory proteins [83].
5 mTOR as a Potential Therapeutic Target
in Osteoarthritis
Recent pre-clinical studies have shown a decrease in the
severity of OA in animal models subjected to pharmaco-
logical inhibition and genetic deletion of mTOR. These
results depict mTOR as a potential therapeutic target in
OA. Specifically, the ability of mTOR to regulate chon-
drocyte survival, cell death, and senescence is promising.
Furthermore, the effect of mTOR modulation on lifespan
has been examined in yeast, C. elegans, Drosophila and
most importantly, mice [86–88]. Harrison et al. [89] re-
ported a significant increase in lifespan in male and female
mice following rapamycin treatment at 600 days of age. It
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would be interesting to track how this treatment results in
the aging of the joints in these mice and whether treatment
with rapamycin protects articular cartilage from degen-
eration and maintains articular cartilage integrity.
Genetic or pharmacological manipulation of mTOR
signalling is time sensitive, since mTOR is essential for the
early stages of cartilage growth and development. Prema-
ture modulation of the mTOR-signaling pathway has dire
consequences on skeletal growth in vivo. In recent years,
inhibition of the mTOR pathway has received substantial
attention as an anti-cancer approach, leading to the clinical
development of rapamycin analogs (rapalogs) (Table 1)
[90]. The mTOR pathway has also been shown to be in-
volved in the development of vascular lesions associated
with antiphospholipid syndrome, an autoimmune disease
[91]. Clinical studies in patients with antiphospholipid
syndrome nephropathy who required transplantation
showed that treatment with sirolimus resulted in no re-
currence of vascular lesions and decreased vascular pro-
liferation on biopsy as compared with patients with
antiphospholipid antibodies who were not receiving sir-
olimus. In rheumatic diseases, rapamycin has been shown
to reduce the disease activity in patients with systemic
lupus erythematosus [92]. In a case study involving a single
patient with scleroderma, treatment with rapamycin
decreased skin tightness and increased the range of motion
of fingers and arms [93]. The beneficial effects of ra-
pamycin have also been reported in a patient with der-
matomyositis [94]. In animal models of systemic sclerosis,
treatment with rapamycin prevents fibrosis in tight-skin
and bleomycin-induced mouse models [95].
Despite these advances, the disease-modifying effects of
rapamycin and its rapalogs have not been tested in OA
clinical studies. As previously discussed, mTOR has a
negative feedback inhibition on the activity of the PI3K/
Akt pathway, and the inhibition of mTOR results in in-
creased activity of the PI3K/Akt/nuclear factor (NF)-jB
pathway, which may increase MMP secretion by chon-
drocytes. Chen et al. [96] propose that a dual inhibition of
PI3K and mTOR may be a potential therapeutic approach
in OA (Fig. 2). Besides this prospect of dual inhibition,
targeting autophagy genes to upregulate autophagy, impart
chondroprotection, and promote articular cartilage home-
ostasis can also be tested.
The side effects observed with mTOR inhibitors may be
a limitation of their use. However, this may be resolved by
preventive and management measures during the course of
treatment with combination therapy. In addition, intra-ar-
ticular delivery of mTOR inhibitors in affected OA joints
could reduce the risk of systemic side effects. As further
Table 1 List of some recent clinical trials with mammalian target of rapamycin inhibitors
Drug name(s) Title of study Trial status References
Sirolimus A pilot study evaluating the use of mTOR inhibitor sirolimus in children and
young adults with desmoid-type fibromatosis
Phase I and II [97]
Gemcitabine ?
rapamycin
Gemcitabine plus rapamycin versus gemcitabine to treat advanced soft tissue
sarcoma
Phase I and II
(completed)
[98]
Sirolimus Pulsed oral sirolimus in autosomal dominant polycystic kidney disease—the
Vienna rap study
Phase III [99]
Everolimus Controlled level everolimus in acute coronary syndromes Phase I and II [100]
Rapamycin Prospective study of rapamycin for the treatment of SLE Phase II [101]





Everolimus and lenalidomide in treating patients with relapsed or refractory
non-Hodgkin or Hodgkin lymphoma
Phase I and II [103]
Everolimus ?
trastuzumab ? vinorelbine
Daily everolimus in combination with trastuzumab and vinorelbine in HER2/
Neu positive women with locally advanced or metastatic breast cancer
Phase III [104]
Rapamycin Neoadjuvant rapamycin in patients undergoing radical cystectomy Phase 0
(completed)
[105]
Temsirolimus Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma Phase III [106]
Temsirolimus ?
hydroxychloroquine
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients




Outcomes in patients with relapsed or refractory multiple myeloma in a phase I
study of everolimus in combination with lenalidomide
Phase I [108]
Temsirolimus ? irinotecan ?
temozolomide
Phase I trial of temsirolimus in combination with irinotecan and temozolomide
in children, adolescents and young adults with relapsed or refractory solid
tumors: a Children’s Oncology Group Study
Phase I and II [109]
HER human epidermal receptor, SLE systemic lupus erythematosus
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validation of rapamycin or other mTOR inhibitors is con-
ducted in pre-clinical studies, it will be essential to dissect
the mTOR-dependent, mTOR-independent, and other off-
target effects of mTOR inhibitors. Overall, the outcomes of
preclinical studies of mTOR modulation in OA, as well as
clinical studies conducted using mTOR inhibitors for the
treatment of cancer and other diseases give credibility to
the use of mTOR inhibitors as a potential and promising
therapeutic target for OA patients.
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